GSK Awarded Up To $200M For Bioterror Drug Program
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority said Wednesday it has awarded GlaxoSmithKline PLC up to $200 million in a groundbreaking effort to help...To view the full article, register now.
Already a subscriber? Click here to view full article